vor 2 Jahren

Life Sciences Report 2017 / 2018

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

12 Life

12 Life Sciences Report – Excellent Conditions for Transfer and Translation “The wide variety of the disciplines in the Gesundheitscampus Brandenburg enables a new quality of future-oriented projects. In the collaborative research project ‘Consequences of age-associated cell and organ functions’ interdisciplinary fundamental research and clinically translational research form the basis for age-adapted, efficient, gentle, and individualized therapies.” BCRT © 2011 Prof. Dr. Andreas Lendlein Director of the Institute of Biomaterial Science of the Helmholtz-Zentrum Geesthacht at Teltow a juxtaposition of experiences and visions, space for communication, as well as suitable service and consulting offerings. The other technology parks include the Co:bios campus in Hennigsdorf, the Luckenwalde Biotechnology Park, the berlinbiotechpark, the Potsdam Biotech Campus, and the Wuhlheide Innovation Park. The construction of an additional technology and start-up center in Berlin by 2021 is planned with the FUBIC in Steglitz-Zehlendorf. In the former US military hospital, between 60 and 80 companies that work with life sciences, health, and climate will be located on approximately 18,600 m 2 of floor space. The Freie Universität (FU) is currently renovating the former office of the president for the FU start-up villa, which will be available in the spring of 2018. In addition, research labs are planned in containers so that the FUBIC can get going well before 2021. Quick translation into clinical practice The metropolitan region offers ideal conditions for close, project-related cooperation between basic researchers, technology developers, and clinical researchers. The Gesundheitscampus Brandenburg, founded on the initiative of the Brandenburg state government in 2015, includes the setup of an inter-university network of the supporting universities (University of Potsdam, Brandenburg University of Technology, and Brandenburg Medical School Theodor Fontane), non-university research institutions, and additional universities in the State, clinics, health insurance funds, associations, and companies. By mid-2018, a joint faculty is expected to be set up by the supporting universities. The establishment of medically-oriented collaborative research in the basic area for the acquisition of competitive third-party funding, a contribution to research into more frequently occurring diseases, and a more robust transfer of knowledge are being pursued here. This will provide a statewide network for cooperation in innovation, networking, and research in Brandenburg. The capital region features a number of topic-specific networks, in which actors along the entire value-added chain jointly research, develop, and market services. These include DiagnostikNet Berlin-Brandenburg (see In vitro Diagnostics chapter), Net PhaSol, and glyconet Berlin-Brandenburg (see Drug Discovery and Development chapter). The use of scientific databases, bioprobes, and large devices as well as access to expertise, patents, and science graduates are crucial for the development of innovative products. The Berlin and Brandenburg universities and research institutions, as well as their technology transfer centers, are excellently positioned for this purpose. Screening Unit The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) hosts the central open access technology platform EU-OPENSCREEN, the ChemBioNet, the Berlin Institute of Health, and the Helmholtz-Initiative für Wirkstoffforschung, the Screening Unit. The Unit provides systematic screening of large compound or genomewide RNAi libraries with state-of-the-art equipment like automated microscopes and microfluidic systems within EU, BMBF, DFG, and regionally funded academic networks. The mission of the platform is to enable access for academic projects to experiments in high-throughput without loss of IP and on a cost basis, which does not restrict access to HTS usage. The Screening Unit is part of the Chemical Biology Platform of the FMP and is also supported by the Max Delbrück Center for Molecular Medicine.

Life Sciences Report 2015 – Hot Topics 13 TRANSLATI ON! Bringing new ideas, products and services to patients is the toughest challenge in biomedical research. At Berlin Health Innovations, the joint technology transfer of Berlin Institute of Health and Charité – Universitätsmedizin Berlin, we are committed to making a powerful difference in translational medicine. We combine our knowhow in the areas of pharmaceuticals, diagnostics and medtech with innovative digital solutions to cope with the covergence of health businesses and to add value to our innovations. We are fast and have advanced instruments for technology transfer. We enable translation – for patients and industry partners worldwide. Discover us under

Publications in English

Publikationen auf deutsch

Clusterreport Verkehr, Mobilität und Logistik
Automotive in der Hauptstadtregion Berlin-Brandenburg
Aerospace Industrie
Biotech- und Pharmaindustrie
Forschung für die Gesundheit
Gesundheitsversorgung und Prävention
Potenzialstudie Medizintourismus Berlin-Brandenburg_2015
Clusterbroschuere Gesundheitswirtschaft
Prävention und Gesundheitsförderung
Rehabilitation in Berlin und Brandenburg
Games Industrie in der Hauptstadtregion Berlin-Brandenburg
Digitale Wirtschaft in Berlin
Fernsehen in der Hauptstadtregion Berlin-Brandenburg
Fashion in Berlin
Best Practice Wireless in der Hauptstadtregion Berlin-Brandenburg
Medien und Kreativwirtschaft in Berlin-Brandenburg
Turbomaschinen und Kraftwerkstechnik
Energienetze und -speicher in der Hauptstadtregion Berlin-Brandenburg
Kreislaufwirtschaft in Berlin
Wasserwirtschaft in Berlin
Energietechnik in der Hauptstadtregion Berlin-Brandenburg
Inkubationsprogramme in der Energiewirtschaft
Service Packages für Unternehmen in Berlin
Unternehmensservice in den Berliner Bezirken
Berlin Partner: Unser Service fuer Sie